Livzon Pharmaceutical Group Inc (000513) — Capital Reinvestment Ratio
Livzon Pharmaceutical Group Inc (000513) has a Capital Reinvestment Ratio of 0.13x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥853.59 Million) in capital expenditures (CN¥108.66 Million). See how leveraged is Livzon Pharmaceutical Group Inc's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Livzon Pharmaceutical Group Inc Capital Reinvestment Ratio (1999–2024)
This chart tracks Livzon Pharmaceutical Group Inc's Capital Reinvestment Ratio across 26 annual periods. Check 000513 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Livzon Pharmaceutical Group Inc (1999–2024)
Year-by-year Capital Reinvestment Ratio for Livzon Pharmaceutical Group Inc from 1999 to 2024. For live market cap and broader valuation context, see Livzon Pharmaceutical Group Inc (000513) total market value.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.19x | CN¥2.98 Billion | CN¥570.16 Million | ▼ -20.8% |
| 2023 | 0.24x | CN¥3.39 Billion | CN¥820.45 Million | ▼ -28.7% |
| 2022 | 0.34x | CN¥2.77 Billion | CN¥940.15 Million | ▼ -50.7% |
| 2021 | 0.69x | CN¥1.90 Billion | CN¥1.31 Billion | ▲ +129.8% |
| 2020 | 0.30x | CN¥2.16 Billion | CN¥646.98 Million | ▲ +32.9% |
| 2019 | 0.23x | CN¥1.77 Billion | CN¥398.00 Million | ▼ -39.8% |
| 2018 | 0.37x | CN¥1.27 Billion | CN¥474.47 Million | ▲ +67.4% |
| 2017 | 0.22x | CN¥1.32 Billion | CN¥294.15 Million | ▼ -22.4% |
| 2016 | 0.29x | CN¥1.28 Billion | CN¥368.46 Million | ▼ -44.0% |
| 2015 | 0.51x | CN¥927.79 Million | CN¥477.13 Million | ▼ -44.6% |
| 2014 | 0.93x | CN¥717.39 Million | CN¥665.52 Million | ▼ -55.6% |
| 2013 | 2.09x | CN¥439.99 Million | CN¥920.00 Million | ▲ +62.9% |
| 2012 | 1.28x | CN¥593.96 Million | CN¥762.30 Million | ▲ +160.6% |
| 2011 | 0.49x | CN¥708.20 Million | CN¥348.83 Million | ▼ -7.4% |
| 2010 | 0.53x | CN¥633.30 Million | CN¥336.95 Million | ▲ +100.4% |
| 2009 | 0.27x | CN¥494.88 Million | CN¥131.41 Million | ▲ +21.4% |
| 2008 | 0.22x | CN¥345.18 Million | CN¥75.52 Million | ▼ -40.4% |
| 2007 | 0.37x | CN¥248.55 Million | CN¥91.28 Million | ▼ -53.9% |
| 2006 | 0.80x | CN¥226.46 Million | CN¥180.45 Million | ▼ -50.0% |
| 2005 | 1.59x | CN¥161.07 Million | CN¥256.72 Million | ▲ +97.4% |
| 2004 | 0.81x | CN¥181.46 Million | CN¥146.48 Million | ▲ +133.9% |
| 2003 | 0.35x | CN¥300.01 Million | CN¥103.56 Million | ▼ -28.8% |
| 2002 | 0.48x | CN¥213.65 Million | CN¥103.62 Million | ▼ -7.7% |
| 2001 | 0.53x | CN¥155.15 Million | CN¥81.48 Million | ▼ -67.1% |
| 2000 | 1.60x | CN¥38.52 Million | CN¥61.49 Million | ▲ +435.3% |
| 1999 | 0.30x | CN¥246.23 Million | CN¥73.44 Million | — |